Variability of 6-mercaptopurine pharmacokinetics during oral maintenance therapy of children with acute leukemia (original) (raw)
Intraindividual variation in 6-mercaptopurine pharmacokinetics during oral maintenance therapy of children with acute lymphoblastic leukaemia
Pierre Lafolie
European journal of clinical pharmacology, 1991
View PDFchevron_right
Pharmacokinetic determinants of 6-mercaptopurine myelotoxicity and therapeutic failure in children with acute lymphoblastic leukemia
Mark Greenberg
Journal of Pediatric Health Care, 1987
View PDFchevron_right
Populationpharmacokinetic and pharmacogenetic analysis of 6-mercaptopurine in paediatric patients with acute lymphoblastic leukaemia
Ahmed Hawwa
British Journal of Clinical Pharmacology, 2008
View PDFchevron_right
Disposition of oral methotrexate in children with acute lymphoblastic leukemia and its relation to 6-mercaptopurine pharmacokinetics
Mark Greenberg
Medical and Pediatric Oncology, 2006
View PDFchevron_right
Adherence to 6-Mercaptopurine in children and adolescents with Acute Lymphoblastic Leukemia
Rawad S Rihani
PLOS ONE
View PDFchevron_right
6-Mercaptopurine in cerebrospinal fluid during oral maintenance therapy of children with acute lymphoblastic leukemia
Pierre Lafolie
Medical oncology and tumor pharmacotherapy, 1988
View PDFchevron_right
HPLC Determination of the Levels of 6-Mercaptopurine Metabolites Suitable for the Clinical Risk Assessment of its Toxicity among Egyptian Children with Acute Lymphocytic Leukemia
Iman Sidhom
Journal of Analytical & Bioanalytical Techniques, 2017
View PDFchevron_right
Value of intravenous 6-mercaptopurine during continuation treatment in childhood acute lymphoblastic leukemia and non-Hodgkin's lymphoma: final results of a randomized phase III trial (58881) of the EORTC CLG
Yves Bertrand
Leukemia, 2005
View PDFchevron_right
Health Technology Assessment of Thiopurine Methyltransferase Testing for Guiding 6-Mercaptopurine Doses in Pediatric Patients with Acute Lymphoblastic Leukemia
Jennifer Renee Donnan
2010
View PDFchevron_right
Personalized Treatment of 6-Mercaptopurine in Thai Children with Acute Lymphoblastic Leukemia
Trai Tharnpanich
2021
View PDFchevron_right
Effect of chemotherapy on the energy and protein metabolism of children near the end of treatment for acute lymphoblastic leukemia
Nachum Vaisman
The American journal of clinical nutrition, 1993
View PDFchevron_right
TPMT*3C as a Predictor of 6-Mercaptopurine-Induced Myelotoxicity in Thai Children with Acute Lymphoblastic Leukemia
Usanarat Anurathapan
Journal of Personalized Medicine
View PDFchevron_right
Should TPMT genotype and activity be used to monitor 6-mercaptopurine treatment in children with acute lymphoblastic leukaemia?
E. Jacqz-aigrain
Journal of Clinical Pharmacy and Therapeutics, 2007
View PDFchevron_right
Symptomatic hypoglycemia in children receiving oral purine analogues for treatment of childhood acute lymphoblastic leukemia
Ottavio Ziino, Maurizio Aricò
Medical and pediatric oncology, 2002
View PDFchevron_right
Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia
Richard Weinshilboum
The Lancet, 1990
View PDFchevron_right
Value of intravenous 6-mercaptopurine during continuation treatment in childhood acute lymphoblastic leukemia and non-Hodgkin's lymphoma: final results of a …
J. Otten
Leukemia, 2005
View PDFchevron_right
Retention of 6-mercaptopurine derivatives by intact cells as an index of drug response in human and murine leukemias
David Kessel
Cancer research, 1969
View PDFchevron_right
Nonadherence to Oral Mercaptopurine and Risk of Relapse in Hispanic and Non-Hispanic White Children With Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group
Leo Mascarenhas
Journal of Clinical Oncology, 2012
View PDFchevron_right
Oral 6-mercaptopurine versus oral 6-thioguanine and veno-occlusive disease in children with standard-risk acute lymphoblastic leukemia: report of the Children's Oncology Group CCG-1952 clinical trial
Archie Bleyer
Blood, 2010
View PDFchevron_right
Hematotoxicity in acute lymphoblastic leukemia children who received 6-Mercaptopurine during maintenance therapy in Indonesia
Dewi Selvina Rosdiana
Journal of International Dental and Medical Research, 2019
View PDFchevron_right
Maintenance therapy of childhood acute lymphoblastic leukemia revisited-Should drug doses be adjusted by white blood cell, neutrophil, or lymphocyte counts?
Richard Weinshilboum
Pediatric blood & cancer, 2016
View PDFchevron_right
A Pharmacokinetic Analysis and Pharmacogenomic Study of 6-mercaptopurine
Peertechz Journals
View PDFchevron_right
Correlation between Nutritional States with Hematological Toxicity in Children with Acute Lymphoblastic Leukemia
HENNY MEDIANI
JURNAL PENDIDIKAN KEPERAWATAN INDONESIA
View PDFchevron_right
Hepatic drug clearance in children with leukemia: Changes in clearance of model substrates during remission-induction therapy
John Pieper
Clin Pharmacol Ther, 1987
View PDFchevron_right
Effect of Food on the Pharmacokinetics of Quizartinib
Melissa Holmes
Clinical Pharmacology in Drug Development
View PDFchevron_right
Effect of reducing the paediatric stavudine dose by half: A physiologically-based pharmacokinetic model
Steve Innes
International Journal of Antimicrobial Agents, 2015
View PDFchevron_right
Cranial irradiation and cerebrospinal fluid levels of 6-mercaptopurine in children with acute leukemia
Riccardo Riccardi
Medical oncology and tumor pharmacotherapy, 1991
View PDFchevron_right